Recent Cl-amidine findings
The transplant pathologist is a central member of the transplant team in all phases of solid organ transplantation and as such, plays an important role in the evaluation of early and late complications after ITx and MVTx. Central among the tools for the pathologist is the mucosal biopsy, used for discerning histopathological
changes in the allograft. The principal complications seen in the late posttransplant phase are acute rejection, chronic rejection, infections, and a variety of other inflammatory conditions. In order to more precisely characterize these conditions, the transplant pathologist must also be able to utilize numerous other laboratory tests and panels of molecular biomarkers that serve as ancillary information to complement the biopsy impression.
Using this array of tools, the transplant pathologist
is now able to provide rapid and precise information regarding the gastrointestinal (GI) transplant complications, a function that allows the clinical team to appropriately and successfully intervene and mTOR inhibitor that helps contribute to the observed improvement in patient and graft survival.”
“Goal: To longitudinally investigate sexual functioning in testicular cancer patients during the first year, and examine the effect of relationship status (with a partner or single) and depressive symptoms on sexual functioning.
Patients and methods: 93 testicular cancer patients (39% single) treated in two large referral centers for testicular cancer filled in the International Index of Erectile Function (IIEF) and CES-D after orchiectomy (T1) and 3 (T2) and 12 (T3) months later.
Results: Orgasmic functioning, overall satisfaction and total sexual functioning decreased between T1
and T2 and increased to an above T1 level at T3. Levels of erectile functioning and intercourse satisfaction were higher at T3 than at T1 and T2. Desire remained stable. Type of treatment did not affect sexual functioning. Singles reported worse sexual functioning at all measurement times than committed patients, and comparable desire. One year after surgery, singles also reported worse sexual functioning on three domains when compared with Crenolanib norms. Depressive symptoms were highest and significantly but weakly related to one domain of sexual functioning at T1, to three domains at T2, and to none at T3. Early depressive symptoms had small to moderate predictive power on sexual functioning at T2, but not at T3.
Conclusion: Sexual functioning, but not desire, fluctuates during the first year after testicular cancer. Type of treatment and depressive symptoms were no risk factors for sexual dysfunction in the longer term. Singles reported more sexual problems than patients in a relationship and norms, they may need more information and guidance concerning their sexuality. Copyright (C) 2009 John Wiley & Sons, Ltd.